Stock 0QIU NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novo Nordisk A/S London S.E.

Equities

0QIU

DK0062498333

Market Closed - London S.E.
Other stock markets
 15:55:00 28/06/2024 BST 		5-day change 1st Jan Change
1,015 DKK +1.67% Intraday chart for Novo Nordisk A/S +2.62% +45.33%
06-28 India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
06-28 NOVO NORDISK : UBS gives a Neutral rating ZD

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.28 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVO NORDISK A/S Stock Novo Nordisk A/S
+45.33% 641B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
A+
NOVARTIS AG Stock Novartis AG
+13.31% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. 0QIU Stock
  5. Ratings Novo Nordisk A/S